William Blair cheers Tesla-Samsung chip deal but keeps TSLA at Hold, citing auto margin woes and valuation concerns.

Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing ...

Cardiff Oncology has reported updated results from its phase 2 colorectal cancer trial, laying out data that it believes can ...

Data analytics firm Verisk said on Wednesday it will buy AccuLynx, which makes software for roofing contractors, for $2.35 ...

PTC Therapeutics secures FDA approval for Sephience in PKU, launching August with analysts projecting strong revenue and ...

Fintel reports that on July 29, 2025, William Blair downgraded their outlook for NeoGenomics (NasdaqCM:NEO) from Outperform ...

In addition, The Allstate Corporation (NYSE:ALL) is taking advantage of a far better auto loss environment and employing ...

The abrupt exit of the former CBER director, who quickly made his mark at the agency with several high-profile and ...

Vinay Prasad, head of the Center for Biologics Evaluation and Research (CBER) at the US Food and Drug Administration (FDA), ...

Andrew Brackman, Diagnostics Analyst, William Blair: just walk through the levers of growth, be that NCCN, metastatic, reimbursement wins, etcetera? John Lott Light, Veracyte: Yeah.

Maggie Nolan, Research Analyst, William Blair: Very good. And, Shiv, you’re a newer face as the President. You came from Accenture, which is obviously a larger scale business in the industry.